Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 530,994 shares of the medical device company's stock, valued at approximately $41,295,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of DexCom as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Congress Asset Management Co. raised its stake in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Proficio Capital Partners LLC acquired a new stake in DexCom during the 4th quarter valued at $5,812,000. Fifth Third Bancorp raised its stake in DexCom by 21.5% during the 4th quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company's stock valued at $2,438,000 after purchasing an additional 5,553 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of DexCom during the 4th quarter valued at $49,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at $454,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DXCM. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Barclays increased their target price on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Finally, Canaccord Genuity Group increased their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.32.

DexCom Trading Up 1.3%

NASDAQ DXCM traded up $1.10 on Friday, reaching $85.96. The company had a trading volume of 4,257,051 shares, compared to its average volume of 4,363,381. The stock's 50 day moving average is $74.67 and its 200-day moving average is $78.72. The stock has a market cap of $33.71 billion, a price-to-earnings ratio of 60.11, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $120.48. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The company's revenue was up 12.5% compared to the same quarter last year. Equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock valued at $6,103,505 over the last three months. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.